John Strony - Concepedia

Author

John Strony

Clinical Research Institute ORCID

Also Known As

J Strony, J T Strony, J. Strony, John Strony, John T. Strony, Keenan Sobol, Nellie Renko

147

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Clinical Research Institute University of Alberta Merck & Co., Inc., Rahway, NJ, USA (United States)Stanford University University of Kentucky

About

John Strony is an author at Clinical Research Institute specializing in medicine, cardiovascular disease, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	2.4K
2	Public Health	5	5	637
3	Health Sciences	2	2	212
4	Biomedical Engineering	2	2	255
5	Engineering	1	1	54

John Strony

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Vorapaxar in the Secondary Prevention of Atherothrombotic Events David A. Morrow, Eugene Braunwald, Marc P. Bonaca, New England Journal of Medicine	2012	927
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes Pierluigi Tricoci, Zhen Huang, Claes Held, New England Journal of Medicine	2011	747
Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes Robert P. Giugliano, Jennifer A. White, Christoph Bode, New England Journal of Medicine	2009	513
Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina John A. Bittl, John Strony, Jeffrey Brinker, New England Journal of Medicine	1995	496
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Christopher P. Cannon, Robert P. Giugliano, Michael A. Blazing, American Heart Journal ThrombosisCardiovascular DiseaseCardiovascular OutcomesImproved ReductionClinical Trials	2008	297
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Richard C. Becker, David J. Moliterno, Lisa K. Jennings, The Lancet Percutaneous Coronary InterventionCardiovascular DiseaseCoronary Artery DiseaseSch 530348Patient Safety	2009	295
Milvexian for the Prevention of Venous Thromboembolism Jeffrey I. Weitz, John Strony, Walter Ageno, New England Journal of Medicine	2021	235
Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention J.Conor O’Shea, Gail E. Hafley, Sally Greenberg, JAMA	2001	230
Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Eric J. Topol, R Bonan, D E Jewitt, Circulation	1993	217
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial E. Magnus Ohman, Matthew T. Roe, Philippe Gabríel Steg, The Lancet ThrombosisCardiovascular DiseaseMedicineCardiovascular PharmacologyP2y12 Inhibition	2017	217

Page 1